Lung Cancer in 2026: Precision Oncology, Biomarkers and Metabolic Strategies

October 14, 2026

Last reviewed: October 15, 2026 | Guide type: Evidence-based clinical education | Topic: Lung cancer, precision oncology and emerging metabolic strategies

Lung cancer is not one disease. It is a collection of biologically different malignancies whose behavior, treatment response and prognosis depend on histology, stage, molecular alterations, immune biology and the patient's overall health.

Modern lung cancer care has advanced considerably through early detection, surgery, radiotherapy, molecular profiling, targeted drugs and immunotherapy. Yet important challenges remain: cancers can become resistant to treatment, some tumors lack actionable molecular targets, access to innovative medicines is uneven, and many patients need better options after their disease progresses.

This guide brings together two complementary perspectives: Lung Cancer in the Era of Precision Oncology and Lung Cancer Beyond Precision Oncology: The Five-Axis Metabolic Trap.

The first perspective explains how genomic alterations can guide treatment. The second explores whether cancer metabolism, mitochondrial function, the tumor microenvironment and immune biology might offer additional ways to address resistance.

The central conclusion: Precision oncology and stage-appropriate cancer treatment remain the clinical foundation. Systems biology and metabolic strategies may generate promising research questions, but the proposed Five-Axis Metabolic Trap has not been validated as an integrated treatment protocol in prospective clinical trials. It should not replace or delay established care.

This is an educational guide, not an individualized treatment recommendation. Drug approvals and clinical guidelines vary by country, cancer subtype, treatment line and biomarker status.

Contents
Executive summary
1. Understanding lung cancer biology
2. What precision oncology actually means
3. The molecular testing checklist
4. Treatment pathways by stage and subtype
5. Why treatment resistance develops
6. The Five-Axis Metabolic Trap
7. Evidence grading: what is established and what is experimental?
8. Nutrition, exercise and supportive care
9. Repurposed drugs and supplements: safety first
10. Questions to ask the oncology team
11. Clinical trials and second opinions
12. Prevention and early detection
Frequently asked questions
References and further reading

Executive Summary: The Most Important Takeaways

Establish the exact diagnosis first. Small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are distinct diseases. NSCLC must also be characterized by histology and, when indicated, molecular and immune biomarkers.
Obtain appropriate molecular testing. Broad molecular profiling is especially important in advanced non-squamous NSCLC. A result can reveal a treatment target that would otherwise be missed.
Understand PD-L1 and genomic biomarkers separately. PD-L1 is a protein-expression biomarker that can help guide immunotherapy decisions. It is not interchangeable with a DNA mutation or gene fusion.
Match treatment to stage and biology. Potential options include surgery, stereotactic radiation, chemoradiotherapy, chemotherapy, targeted therapy and immunotherapy. These approaches are not interchangeable, and combinations depend on the clinical context.
Expect resistance to require reassessment. When cancer progresses, repeat tissue or blood-based testing may identify an acquired alteration or another explanation that changes the available options.
View metabolic cancer research critically. Cancer cells do alter how they use glucose, fats, amino acids and mitochondria. However, demonstrating a mechanism in a laboratory does not prove that a diet, supplement or repurposed medicine can control a patient's cancer.
Protect nutrition, muscle and quality of life. Adequate nutrition, appropriate physical activity, smoking cessation and symptom management are important parts of care. Severe restriction, unintended weight loss and unsupervised supplement combinations can be harmful.

For established treatment guidance, consult the National Cancer Institute's lung cancer information hub and the latest ASCO thoracic cancer guidelines.

1. Understanding Lung Cancer Biology

1.1 Non-small cell lung cancer versus small cell lung cancer

Approximately 85% of lung cancers are NSCLC and most of the remainder are SCLC, although the proportions vary among populations and classification systems. These categories differ in pathology, typical molecular findings, patterns of spread and treatment strategies.

Feature	Non-small cell lung cancer (NSCLC)	Small cell lung cancer (SCLC)
Common categories	Adenocarcinoma, squamous cell carcinoma and other less common forms	High-grade neuroendocrine carcinoma
Typical biology	Heterogeneous; some tumors have specific actionable molecular alterations	Often rapidly proliferative, with early spread and frequent treatment resistance
Molecular testing	Particularly important in advanced disease; the testing panel depends on histology and context	Routine driver-directed treatment options are more limited, although research and treatment options are evolving
Treatment principles	May include surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy	Often includes platinum-based chemotherapy, immunotherapy in appropriate settings and radiotherapy according to stage

The distinction is clinically important. A result or treatment strategy that is relevant to EGFR-mutated adenocarcinoma should not automatically be generalized to SCLC or every other lung cancer.

1.2 Three levels of tumor information

A useful starting framework separates lung cancer into three overlapping layers:

Histology: What type of cancer is present under the microscope?
Genomic biology: Which acquired molecular alterations are present, and are any linked to an effective targeted treatment?
Immune and clinical context: How does PD-L1 expression, disease stage, performance status, prior treatment and the patient's broader health affect the choices?

A single mutation report cannot answer every clinical question. Molecular data must be interpreted alongside the pathology report, imaging, staging, symptoms, treatment history and the goals of care.

1.3 Lung cancer in people who have never smoked

A lung cancer diagnosis in a never-smoker is entirely possible. Never-smoker status does not exclude lung cancer, and the absence of a smoking history should not be used to dismiss symptoms or delay appropriate diagnostic evaluation.

Some never-smokers with lung adenocarcinoma have actionable alterations such as EGFR mutations or ALK and ROS1 rearrangements. But patient characteristics cannot substitute for tumor testing: a person's age, sex or smoking history does not reliably establish which mutation their cancer carries.

Smoking remains a major preventable risk factor. Other exposures and risk factors include radon, secondhand smoke, occupational carcinogens, air pollution and certain underlying lung conditions. Risk reduction and treatment decisions should reflect the individual situation.

2. What Precision Oncology Actually Means

Precision oncology attempts to match cancer treatment to biologically relevant features of an individual tumor. In lung cancer, this can mean selecting a targeted medicine for a specific driver alteration or using PD-L1 expression and other clinical information to help select immunotherapy.

The most important benefit is practical: a well-validated molecular result can identify a treatment that is more suitable than a generic treatment approach for that particular tumor.

2.1 Actionable biomarkers in NSCLC

The following are examples of alterations that may guide treatment in particular clinical settings. The presence of an alteration does not guarantee that every drug targeting it is appropriate, accessible or effective for every patient.

Biomarker or alteration	Why it matters	Clinical interpretation
EGFR	Specific mutations can predict sensitivity to EGFR-directed medicines.	The exact variant matters. Common sensitizing mutations and exon 20 insertions are not treated identically.
ALK	ALK rearrangements can create a target for ALK inhibitors.	Fusion detection and prior treatment history influence the available options.
ROS1	ROS1 fusions can be therapeutically actionable.	ROS1-directed medicines are available for selected patients with advanced disease.
KRAS G12C	This specific KRAS variant can be targeted by selected inhibitors.	Not all KRAS mutations are equivalent, and approved treatment indications differ.
BRAF V600E	Can identify a tumor with a targetable signaling alteration.	Therapy selection depends on the specific alteration and applicable guideline or approval.
MET exon 14 skipping	Can identify tumors eligible for MET-directed treatment.	Testing technology must be suitable for detecting the relevant alteration.
RET fusion	Can predict sensitivity to RET-directed therapy.	Fusion detection is important; testing platforms differ in their ability to detect fusions.
NTRK fusion	May support tumor-agnostic targeted treatment under specific indications.	Rare fusions can be missed if testing is too narrow.
HER2 / ERBB2	Some activating mutations and protein-expression findings have therapeutic relevance.	A mutation and protein overexpression are different biomarkers and must not be treated as interchangeable.
PD-L1 expression	May help determine whether immunotherapy alone or in combination is appropriate.	PD-L1 is an expression assay, not a genomic mutation. It does not guarantee response.

This is a practical overview rather than a complete prescribing table. Other biomarkers, combined alterations and new drug indications may be relevant. The treating oncology team should use current regional guidelines, approved indications and a validated laboratory report.

2.2 Why broad molecular profiling can be better than testing one gene at a time

When appropriate, comprehensive genomic profiling can examine many potentially relevant alterations from one tumor sample. Next-generation sequencing (NGS) can help identify variants, insertions and deletions, amplifications and gene fusions, depending on the platform and assay design.

Some laboratories use both DNA-based and RNA-based methods because different alterations are best detected using different technologies. A narrow test can miss a relevant alteration outside its scope.

For advanced non-squamous NSCLC, broad molecular testing is generally an important part of treatment planning. Testing decisions in squamous disease and earlier-stage disease depend on the clinical setting and current guideline recommendations.

2.3 Tissue biopsy versus liquid biopsy

A tissue biopsy can establish the diagnosis, provide histology and supply material for molecular testing. A liquid biopsy analyzes cancer-related material—commonly circulating tumor DNA—in blood.

Liquid biopsy can be useful when tissue is inadequate, difficult to obtain or when a new molecular assessment may help explain resistance. However, a negative blood test does not necessarily prove that the tumor lacks an actionable alteration. Some cancers release little detectable tumor DNA into circulation.

Practical point: Ask the oncology team whether a negative or incomplete liquid-biopsy result should be followed by tissue testing, repeat testing or another assessment. The appropriate approach depends on the clinical situation and the risks of obtaining another sample.

3. The Molecular Testing Checklist

Before deciding that a tumor has no targetable option, patients and caregivers can use the following checklist to clarify what has already been tested.

Confirm the pathology. Is the diagnosis adenocarcinoma, squamous NSCLC, SCLC or another histologic type? Has the pathology been reviewed if the diagnosis is uncertain?
Check the sample quality. Was there enough tumor material for the planned tests? Was the specimen obtained before or after a major change in the disease?
Ask about broad genomic profiling. Was an appropriate multigene panel performed, rather than only one or two individual tests?
Confirm the scope. Did the panel cover the relevant mutations, insertions/deletions and fusions? Was RNA-based testing used when appropriate?
Check PD-L1 testing. Is an interpretable PD-L1 result available if it is relevant to treatment selection?
Clarify uncertain results. Are any findings variants of uncertain significance rather than established treatment targets?
Review the results with a thoracic oncologist. A result needs to be interpreted with stage, pathology, performance status, previous therapies and current approvals.

A variant of uncertain significance should not automatically be treated as an actionable mutation. Likewise, a laboratory report listing many alterations does not mean that there are proven medicines for every one of them.

For more detail, see the National Cancer Institute's NSCLC treatment summary and ASCO's thoracic oncology guideline updates.

4. Treatment Pathways by Stage and Subtype

There is no single best treatment for every lung cancer. Treatment planning begins with the exact diagnosis, the stage and whether the cancer can be removed surgically or treated with a potentially curative local approach.

Clinical setting	Common treatment considerations	Key decision
Early-stage NSCLC	Surgery may be preferred when feasible. Stereotactic body radiotherapy or another local approach may be appropriate for selected patients. Perioperative or postoperative systemic treatment is considered in appropriate circumstances.	Is the tumor resectable, and what additional treatment is indicated by the stage and tumor characteristics?
Locally advanced NSCLC	A multidisciplinary team may consider surgery, chemotherapy, radiation, immunotherapy or a combined approach. Some unresectable tumors are treated with chemoradiotherapy followed by appropriate consolidation treatment.	What is the safest evidence-supported plan for local control and the risk of distant recurrence?
Metastatic NSCLC with an actionable driver	A biomarker-matched targeted therapy may be preferred in a suitable treatment setting. Chemotherapy, immunotherapy, radiation or other approaches may also become relevant depending on the circumstances.	Which treatment best matches the exact molecular alteration, disease distribution and treatment history?
Metastatic NSCLC without an established actionable driver	Immunotherapy alone, chemotherapy plus immunotherapy, chemotherapy or other guideline-supported regimens may be considered.	How do PD-L1, histology, comorbidities and other clinical factors influence the choice?
Small cell lung cancer	Limited-stage disease often involves chemotherapy and radiation. Extensive-stage disease is commonly treated with systemic therapy, including immunotherapy in appropriate settings. Later-line options continue to evolve.	Which stage-specific regimen and subsequent options are appropriate for this patient?

These categories are not prescriptions, and they do not list every approved regimen. Treatment choices must be individualized according to contemporary guidelines and the local availability of medicines.

4.1 Targeted therapy is not the same as immunotherapy

Targeted therapies act on particular molecular pathways or alterations within cancer cells. Immunotherapies such as immune checkpoint inhibitors work by altering the interaction between the immune system and the cancer.

These mechanisms have different benefits, limitations and toxicity profiles. In some molecular subtypes, a targeted drug is the preferred initial treatment. In other situations, immunotherapy or a combination approach may be more appropriate.

It is important that potentially actionable molecular results are reviewed before starting a treatment that could affect the later sequencing of therapies, whenever the patient's clinical condition allows. Urgent clinical circumstances can require treatment decisions before every result is available; this is a decision for the oncology team.

4.2 What is changing in 2026?

The treatment landscape continues to change through new indications, revised treatment sequences, drugs developed for uncommon molecular subtypes and therapies for disease that has progressed after previous treatment.

For example, the US Food and Drug Administration approved taletrectinib for locally advanced or metastatic ROS1-positive NSCLC in June 2025. In November 2025, the FDA granted traditional approval to tarlatamab for certain adults with extensive-stage SCLC progressing on or after platinum-based chemotherapy. These are examples of evolving options, not evidence that the medicines are appropriate for every patient.

An approval in one country does not automatically mean that a medicine is registered, reimbursed or available in another. Patients should confirm locally applicable indications, eligibility criteria, access arrangements and monitoring requirements.

5. Why Treatment Resistance Develops

One of the most important limitations of modern oncology is that a treatment can work initially and later stop working. This is not always evidence that the original diagnosis or treatment selection was wrong.

Tumors contain diverse populations of cells. Some cells may already have resistance-related features before treatment begins. Others may acquire new alterations or adapt to the biological pressures imposed by therapy.

5.1 Common mechanisms of resistance

Secondary genetic alterations: A tumor can acquire changes that reduce drug binding or change the pathway being targeted.
Bypass signaling: Cancer cells may activate alternative pathways that restore growth and survival despite inhibition of the original target.
Histologic transformation: In some cases, the cancer changes its cellular characteristics, affecting both its behavior and treatment options.
Metabolic adaptation: Cancer cells may alter the relative use of glucose, amino acids, fatty acids and mitochondrial energy production.
Tumor microenvironment changes: Stromal cells, blood vessels, extracellular matrix and immune cells can influence drug delivery and tumor survival.
Immune escape: Cancer cells can evade immune recognition or establish conditions that reduce the effectiveness of antitumor immune responses.

These processes are active research areas. However, the presence of a resistance mechanism in a laboratory model does not necessarily establish an effective way to overcome it in human patients.

5.2 What should happen when the cancer progresses?

Progression should prompt a structured reassessment rather than an automatic assumption that every treatment option has been exhausted.

Depending on the case, the oncology team may reconsider the diagnosis, repeat imaging, review adherence and treatment exposure, assess whether a new biopsy or circulating tumor DNA test is appropriate, and evaluate clinical trials or other guideline-supported treatments.

A new molecular result can occasionally identify another targeted option. In other cases, progression is not explained by a single actionable alteration, and a different systemic or local strategy may be more appropriate.

Key principle: Use molecular testing to guide decisions where evidence supports it. Do not assume that every proposed metabolic or repurposed-drug strategy can reverse resistance.

6. Beyond Precision Oncology: The Five-Axis Metabolic Trap

The Five-Axis Metabolic Trap is a proposed systems-biology framework described in the second source article. It organizes several research hypotheses around the idea that cancer survival depends on more than one mutation or signaling pathway.

The five axes are:

Metabolic pressure.
Mitochondria and cancer stem cells.
Cytoskeletal and mitotic disruption.
Tumor microenvironment modulation.
Immune restoration.

The proposal is that multiple biological systems interact and may contribute to treatment resistance. It therefore asks whether complementary strategies could eventually improve outcomes when added to established oncology treatment.

This is a reasonable research question. It is not yet a validated multi-drug treatment protocol. The five axes should be understood as an organizing hypothesis that requires clinical testing, not as five proven treatments.

Axis	Biological concept	Examples discussed in the research framework	Clinical evidence status
1. Metabolic pressure	Glucose handling, insulin signaling and nutrient-sensing pathways	Dietary patterns, metformin, berberine and selected nutraceuticals	The biological rationale is under investigation. These interventions are not established as a combined lung-cancer treatment.
2. Mitochondria and cancer stem cells	Energy production, mitochondrial adaptation and treatment-persistent cell populations	Doxycycline, ivermectin, melatonin, resveratrol and genistein	Much of the proposed anticancer rationale is mechanistic or preclinical. Clinical benefit from this combination has not been established.
3. Cytoskeletal and mitotic disruption	Microtubules, cell division, migration and invasion	Mebendazole as an investigational repurposed drug; established microtubule-targeting chemotherapy as a separate clinical category	Some conventional microtubule-targeting medicines have established roles in oncology. That evidence cannot be automatically transferred to mebendazole.
4. Tumor microenvironment	Inflammation, angiogenesis, stromal interactions and immune suppression	Propranolol, curcumin, omega-3 fatty acids, statins, vitamin D and modified citrus pectin	Effects vary by intervention and indication. The proposed combined approach is not established treatment for lung cancer.
5. Immune restoration	Antitumor immune surveillance and the conditions affecting immune-cell function	Nutritional adequacy, lifestyle measures and selected immune-modulating products	Supportive care is important, but indiscriminate immune stimulation or supplement-based immune treatment has not been shown to reproduce the effects of approved immunotherapy.

The examples above summarize interventions discussed in the source framework. Inclusion in this table is not a recommendation, a ranking of efficacy or an endorsement of a regimen.

Axis 1: Metabolic pressure

Cancer cells can change how they use nutrients and energy. Glucose metabolism, mitochondrial respiration, amino-acid use and other pathways can interact with oncogenic signaling. The relative importance of each pathway varies across tumors and treatment settings.

The source article discusses low-carbohydrate diets, ketogenic diets, time-restricted eating, intermittent fasting, metformin, berberine, curcumin, green tea compounds and sulforaphane as ways to influence aspects of metabolic signaling.

The critical distinction is between changing a laboratory biomarker and improving a clinical outcome. Reducing circulating glucose or changing an insulin-related measurement does not itself establish that a diet or supplement shrinks a lung tumor, delays progression or extends survival.

There is also a biological and practical limitation to the idea of starving cancer by restricting nutrients: cancer cells can use alternative pathways, while the patient still requires adequate energy and protein to maintain muscle, immune function and treatment tolerance.

Dietary interventions for people with lung cancer should therefore prioritize nutritional adequacy and the patient's treatment needs. Ketogenic diets and fasting regimens should not be presented as proven anticancer therapies.

Axis 2: Mitochondria and cancer stem cells

Mitochondria perform functions beyond energy production, including roles in cell signaling, redox balance and programmed cell death. Research into tumor heterogeneity has raised questions about whether certain surviving cell populations depend on mitochondrial pathways during treatment.

Doxycycline, ivermectin and several nutraceuticals have been studied for effects on cellular pathways in experimental models. These findings can support further research, but they do not establish safe, effective doses or meaningful clinical benefit in lung cancer.

In particular, an experimental effect on mitochondria or cells described as cancer stem cells should not be interpreted as evidence that a medicine eliminates cancer stem cells in a patient.

Axis 3: Cytoskeletal and mitotic disruption

Microtubules help cells divide and transport material within the cell. Several established chemotherapy medicines affect microtubule function and have defined clinical roles in selected cancers, including lung cancer.

Mebendazole has attracted research interest because laboratory studies suggest that it can affect microtubules and other cancer-related processes. However, its established antiparasitic use does not establish it as an effective treatment for lung cancer.

A repurposed medicine must still demonstrate clinically useful exposure, appropriate dosing, safety, efficacy and compatibility with other treatments. Those questions cannot be answered by mechanism alone.

Axis 4: Tumor microenvironment modulation

Tumors interact with surrounding immune cells, fibroblasts, blood vessels, connective tissue and inflammatory signaling pathways. This environment can affect tumor growth, immune activity, metastatic behavior and treatment response.

Propranolol, curcumin, omega-3 fatty acids, statins, vitamin D and modified citrus pectin are among the interventions discussed in the source framework because they can affect certain biological pathways under particular conditions.

The clinical implication must remain cautious. Evidence that an intervention changes inflammation, angiogenesis or another laboratory marker is not the same as evidence that it controls lung cancer. Some medicines also carry cardiovascular, bleeding, metabolic or other risks that require individual assessment.

Axis 5: Immune restoration

Immune checkpoint inhibitors have demonstrated that immune-directed treatment can produce substantial and sometimes durable responses in appropriately selected people. They have also shown that immune treatment can cause serious inflammatory adverse effects.

The phrase "immune restoration" should not be taken to mean that taking a collection of supplements will improve immunotherapy. Immune function is influenced by the tumor, treatment, nutrition, infections, underlying conditions and the surrounding biological environment.

Correction of a documented nutrient deficiency may be appropriate for general health. It does not automatically become a cancer treatment, and indiscriminate use of immune-modulating products during immunotherapy can be inappropriate.

6.1 Why the five axes must be tested together before clinical claims are made

The Five-Axis framework describes several interacting biological processes. Its strength as a research concept is that it encourages investigators to ask whether more than one mechanism contributes to resistance.

Its central limitation is that the complete intervention strategy has not been established by prospective clinical trials demonstrating improved progression-free survival, overall survival, quality of life or treatment tolerance in lung cancer.

A clinically useful evaluation would need to specify the exact intervention, dose, treatment context, patient population, interaction monitoring and measurable outcomes. Ideally, randomized studies would compare standard treatment with the same standard treatment plus the proposed adjunctive intervention.

Until such evidence exists, the five axes are best regarded as a hypothesis-generating framework for research.

7. Evidence Grading: What Is Established and What Is Experimental?

Cancer information is often confusing because mechanistic papers, animal studies, observational reports, early clinical studies and randomized trials can all be discussed using the same language of "promising research."

This guide uses the following editorial evidence labels to make the differences more visible. These are reader-facing categories, not a formal GRADE assessment of each individual intervention.

Editorial label	Evidence category	How to interpret it
Established clinical care	Supported by applicable clinical guidelines, regulatory indications and relevant clinical evidence	May be part of standard treatment when appropriate for the patient's diagnosis, stage and circumstances.
Supportive care	Interventions directed at nutrition, symptoms, function, quality of life or general health	Can be an important component of care without being a direct anticancer treatment.
Emerging clinical evidence	Early human studies, limited clinical data or a developing indication	May justify further study or carefully selected clinical use; applicability must be checked.
Preclinical or mechanistic evidence	Laboratory experiments, animal models or biological pathway studies	Generates hypotheses but does not establish a benefit for patients.
Unproven treatment claim	No convincing evidence that the intervention improves meaningful clinical outcomes in the relevant lung-cancer setting	Should not be promoted as an effective treatment or used to replace established care.

7.1 The evidence ladder matters

A responsible assessment asks several questions before drawing a treatment conclusion:

Was the effect observed in cells, animals or people? A striking result in a cell line may not be reproducible at safe drug concentrations in a patient.
Was a clinical outcome measured? A change in a laboratory marker is not the same as longer survival, delayed progression or improved symptoms.
Was there a suitable comparison group? Small uncontrolled studies are vulnerable to selection bias, differences in baseline health and other explanations for an apparent response.
Is the finding relevant to this lung-cancer subtype? A result in another cancer type cannot automatically be transferred to NSCLC or SCLC.
Has independent research reproduced the result? Replication and appropriate study design increase confidence.
Are harms and interactions understood? A product that appears inexpensive or familiar may still cause toxicity or interfere with treatment.

7.2 Why low-cost interventions deserve research—but not lower evidence standards

The cost of cancer treatment is a legitimate concern. Commercial incentives can influence which treatments receive research investment, and low-cost interventions may be difficult to develop into large, adequately funded trials.

That concern supports better independent research and fairer access to proven care. It does not establish that an inexpensive intervention works simply because it is inexpensive, natural or off-patent.

The same principle applies to expensive drugs: price, publicity and regulatory status are not substitutes for examining the magnitude of benefit, the quality of evidence, toxicities, alternatives and patient preferences.

The appropriate response to gaps in evidence is to identify them clearly, fund good research where justified and avoid promising patients benefits that have not been demonstrated.

8. Nutrition, Exercise and Supportive Care

Supportive care should be integrated with cancer treatment rather than postponed until all anticancer options have been exhausted. Its goals include relieving symptoms, maintaining function, preventing avoidable complications and helping patients tolerate the treatment plan.

8.1 Nutrition and weight maintenance

People with lung cancer may experience reduced appetite, nausea, taste changes, fatigue, swallowing difficulties or unintended weight loss. Some experience muscle loss even when body weight appears relatively stable.

A practical nutritional plan can include:

Adequate energy and protein tailored to the patient's needs.
Meals and snacks that are manageable when appetite is poor.
Assessment for unintentional weight loss, malnutrition and muscle loss.
Referral to a dietitian experienced in oncology when necessary.
Monitoring and treatment of symptoms that interfere with eating.

A highly restrictive diet may worsen nutritional problems during a period when maintaining strength is important. A ketogenic diet, prolonged fast or other restrictive plan should not be undertaken as an anticancer treatment without close discussion with the treating team.

8.2 Physical activity and muscle preservation

Physical activity should be adapted to the patient's condition. When clinically appropriate, walking, resistance exercise and rehabilitation can help preserve function and independence.

People with severe breathlessness, bone metastases, significant anemia, dizziness, heart problems or other limitations may need a supervised plan. Exercise recommendations should account for treatment effects, fall risk, pain and any restrictions arising from the disease.

8.3 Smoking cessation and exposure reduction

Stopping smoking remains worthwhile after a lung cancer diagnosis. The oncology team can discuss behavioral support and appropriate smoking-cessation medicines. Avoiding secondhand smoke and addressing relevant environmental or occupational exposures are also sensible measures.

Smoking cessation should be presented as supportive risk reduction, not as a substitute for cancer treatment or as a reason to blame patients for their disease.

8.4 Sleep, symptoms and emotional health

Pain, cough, breathlessness, anxiety, sleep disturbance and depression can affect day-to-day functioning. Early assessment and appropriate management can improve the patient's experience during treatment.

Palliative care can be provided alongside active anticancer treatment. It focuses on symptom relief, communication and quality of life; it does not automatically mean stopping treatment.

8.5 Vitamin D and other nutritional supplements

Correction of a documented vitamin deficiency may be clinically appropriate, but that is different from using a supplement to treat a lung tumor. Routine high-dose supplementation without an identified need is not established as a cancer-control strategy.

Supplement use should be reviewed in the context of kidney and liver function, the patient's medicines, planned procedures and the treatment's potential interactions.

9. Repurposed Drugs and Supplements: Safety First

Drug repurposing investigates whether a medicine developed for one condition may have a useful role in another. It can be a valuable research strategy because the medicine's properties may already be partly characterized.

However, a medicine approved for an infection, diabetes, cardiovascular disease or another condition is not automatically effective or safe as an anticancer treatment. Cancer-related doses, drug exposure, treatment duration and combinations may differ substantially from established use.

9.1 Examples often discussed in metabolic cancer research

Intervention	Research interest	Practical interpretation
Metformin	Metabolic signaling and cellular energy pathways	Use for an established medical indication where appropriate. Anticancer benefit in lung cancer should not be assumed.
Ivermectin	Preclinical studies of signaling, cell survival and cellular stress	Not an established lung-cancer treatment. Laboratory findings do not justify self-medication.
Mebendazole	Experimental effects on microtubules and other cancer-related pathways	Antiparasitic approval does not demonstrate clinical effectiveness against lung cancer.
Doxycycline	Experimental effects on mitochondrial protein synthesis and cell biology	Antibiotic use should be based on an appropriate medical indication or a properly monitored study.
Berberine	Metabolic and signaling effects in laboratory research	Product composition, adverse effects and drug interactions matter; lung-cancer efficacy is not established.
Curcumin and green tea extracts	Experimental anti-inflammatory, metabolic and cellular effects	Laboratory activity does not establish tumor control; concentrated extracts can cause adverse effects or interactions.
Melatonin and resveratrol	Research on sleep, circadian biology, mitochondrial function and cell signaling	Potential supportive effects should not be confused with proven anticancer efficacy.
Propranolol, statins and omega-3 supplements	Research into inflammation, vascular biology and other pathways	Do not start or stop these products for cancer purposes without reviewing the indication, risks and evidence with a clinician.

This table describes research topics, not an anticancer protocol. It intentionally does not provide doses or instructions for combining these medicines.

9.2 Potential interactions with cancer treatment

Some supplements and medicines can alter drug absorption, metabolism, transport or clearance. Others can increase bleeding risk, affect blood sugar, strain the liver or kidneys, or produce effects that overlap with those of cancer treatment.

The National Cancer Institute explains that complementary products can interact with anticancer medicines and that evidence for many combinations remains limited. Patients should disclose supplements, herbs, concentrated extracts and non-prescription drugs to their oncology team and pharmacist.

Read the NCI resource on cancer therapy interactions with foods and dietary supplements.

9.3 What to avoid

Do not replace an established treatment with a self-designed metabolic or repurposed-drug protocol.
Do not interpret animal data, testimonials or an uncontrolled case report as proof that a drug treats lung cancer.
Do not combine multiple off-label medicines without a clinician reviewing interactions and monitoring.
Do not stop targeted therapy, immunotherapy, chemotherapy or prescribed supportive medicines without medical advice.
Do not assume that an unregulated supplement has consistent ingredients, reliable manufacturing or proven safety.
Do not begin a fasting regimen or a severe carbohydrate-restricted diet if it risks malnutrition or interferes with the treatment plan.

Important: A patient with progressing or advanced cancer should not be made to feel that they have failed by not adopting a particular diet or supplement plan. Treatment outcomes depend on many factors beyond personal lifestyle choices.

10. Questions to Ask the Oncology Team

A focused consultation can help patients understand which decisions matter most and which uncertainties remain. Consider bringing these questions to the next appointment.

Diagnosis and staging

What is the exact histological diagnosis and current stage?
Has the cancer spread to the brain, bones, liver or other sites, and is any additional assessment needed?
Has the pathology been reviewed by a specialist thoracic pathologist if necessary?

Molecular and immune testing

Has broad molecular profiling been completed where appropriate?
Were relevant gene fusions and other alterations covered by the assay?
Is PD-L1 expression available and relevant to this treatment decision?
If the blood-based test was negative or incomplete, should tissue testing or another approach be considered?

Treatment options

What is the goal of treatment in this setting: cure, lowering recurrence risk, controlling the disease or relieving symptoms?
What are the expected benefits, major risks and alternatives to the proposed treatment?
Would a second opinion from a thoracic oncology specialist or a multidisciplinary tumor board be useful?
Could a clinical trial provide an appropriate option now or after progression?

Nutrition, exercise and complementary products

Am I at risk of malnutrition or muscle loss?
Would an oncology dietitian or rehabilitation professional be useful?
Could any of my supplements, herbs or repurposed medicines interact with my current treatment?
Is there a clinical trial evaluating the specific metabolic intervention being proposed?

Planning for progression

If this treatment stops working, what reassessment would be needed?
Would repeat genomic testing be useful, and what would the result change?
What is the plan for managing symptoms, treatment side effects and quality of life?

11. Clinical Trials and Second Opinions

Clinical trials may provide access to investigational targeted medicines, new combinations, immunotherapies and approaches aimed at treatment resistance. They are also a way to evaluate whether promising laboratory findings translate into meaningful outcomes for patients.

A clinical trial should have a clearly defined intervention, eligibility criteria, monitoring plan and outcome measures. An early-phase study may primarily investigate dose and safety rather than prove that a treatment extends survival.

When considering a trial, ask:

What is the primary purpose of the study?
Is the treatment being tested alone or with standard care?
What are the known and potential risks?
Will participation affect access to other treatments?
Are travel, treatment and follow-up costs covered?
Will the study measure outcomes meaningful to patients, such as disease control, survival, symptoms and quality of life?

Useful resources include:

Trial registries change frequently. Confirm recruiting status, location, eligibility criteria and the latest protocol with the research team. A trial that appears scientifically promising may not be appropriate for an individual patient.

12. Prevention and Early Detection

12.1 Screening is not the same as diagnostic testing

Low-dose CT screening can reduce lung cancer mortality in selected higher-risk populations. It is not a universal screening test for everyone, and it involves potential harms, including false-positive findings, follow-up investigations and overdiagnosis.

Eligibility criteria differ by country and may change as guidelines evolve. People with a substantial smoking history should discuss whether they meet their local screening criteria. New or concerning symptoms require clinical evaluation rather than simply waiting for the next screening scan.

The National Cancer Institute summarizes the evidence and limitations of lung cancer screening using low-dose CT.

12.2 Risk reduction

Important measures include avoiding tobacco, seeking help to stop smoking, reducing secondhand smoke exposure and addressing relevant workplace or environmental risks. Appropriate radon assessment and mitigation may be important in areas where radon exposure is a concern.

These measures lower avoidable risks but cannot eliminate all lung cancer risk. Lung cancer can occur in people who have never smoked and in people who have followed healthy lifestyles.

12.3 Do not ignore persistent symptoms

Persistent or worsening cough, coughing up blood, unexplained weight loss, chest pain, hoarseness or increasing breathlessness warrant medical assessment. These symptoms have many possible causes, but they should not be dismissed solely because a person never smoked or previously had a normal test.

Severe breathlessness, substantial coughing of blood, new confusion, fainting or sudden neurological symptoms require urgent medical attention.

Conclusion: Integrate Precision Oncology With Evidence, Not Assumptions

The future of lung cancer care is likely to involve increasingly sophisticated integration of molecular profiling, pathology, imaging, immunology, clinical characteristics and patient preferences. The challenge is to translate this expanding scientific understanding into better outcomes without confusing biological plausibility with proven benefit.

Precision oncology has already changed clinical practice by matching treatments to particular tumor alterations and by improving decision-making across several stages of disease. It remains imperfect, and resistance is a genuine challenge. Those limitations create a strong rationale for further research into metabolism, mitochondrial biology, the tumor microenvironment and immune escape.

The Five-Axis Metabolic Trap offers one way to organize these research questions. Its hypotheses deserve careful evaluation, but the integrated framework should not be represented as an established treatment strategy. Individual repurposed drugs, dietary approaches and supplements must be assessed separately, using the same standards of efficacy and safety applied to other medical interventions.

For patients and caregivers, the practical priorities are clear: establish the correct diagnosis, understand the stage, confirm appropriate biomarker testing, review evidence-supported treatment options, protect nutrition and function, and seek expert guidance when the disease progresses. When complementary interventions are considered, transparency about uncertainty and the prevention of treatment interactions are essential.

The goal is not to choose between precision oncology and systems biology. It is to use established treatments where they are supported, test promising new approaches rigorously, and ensure that every decision remains grounded in the individual patient's biology, clinical circumstances, values and goals.

Frequently Asked Questions

1. What is precision oncology in lung cancer?

Precision oncology uses information about the tumor's molecular alterations, pathology and other clinical biomarkers to guide treatment. In selected NSCLC cases, testing may reveal an alteration for which a targeted medicine is available. It can also help clinicians choose among other evidence-supported options.

2. Should every patient with lung cancer have molecular testing?

The appropriate testing depends on the cancer type, stage and clinical setting. Broad molecular profiling is particularly important in advanced non-squamous NSCLC. Your oncology team can confirm which genomic and protein-expression tests are recommended in your specific situation.

3. What is the Five-Axis Metabolic Trap?

It is a proposed research framework covering metabolic pressure, mitochondria and cancer stem cells, cytoskeletal disruption, tumor microenvironment modulation and immune restoration. The complete framework has not been established as an effective standard lung-cancer treatment in prospective clinical trials.

4. Can a ketogenic diet or fasting treat lung cancer?

Neither a ketogenic diet nor fasting should be considered a proven lung-cancer treatment. Research into metabolism is ongoing, but changing glucose or insulin levels does not establish that a dietary intervention controls a tumor. Severe dietary restriction may also cause weight loss or malnutrition. Discuss significant dietary changes with your oncology team.

5. Can ivermectin, mebendazole or doxycycline be used as lung-cancer treatments?

These medicines have been discussed in cancer research, and some have shown biological effects in laboratory studies. That does not establish clinical benefit in lung cancer. They should not be self-prescribed or substituted for established treatment. Any investigational use requires appropriate medical oversight and attention to interactions and risks.

6. Why can targeted therapy stop working?

Cancer cells can acquire additional alterations, activate bypass pathways or undergo other biological changes that reduce sensitivity to treatment. Some cancers also adapt through changes in metabolism and their surrounding environment. Reassessment at progression can help identify which options remain appropriate.

7. Can liquid biopsy replace a tissue biopsy?

Not in every situation. Blood-based circulating tumor DNA testing can be helpful, but a negative result may occur when insufficient tumor DNA is detected. Tissue may still be needed to establish histology or clarify molecular findings. The right approach depends on the patient's circumstances and the quality of the available sample.

8. Can supplements improve the effectiveness of immunotherapy?

Some supplements affect biological processes involved in immunity, but this does not establish that they improve clinical responses to immune checkpoint inhibitors. Supplements can also interact with treatment. Review every product with the oncology team and pharmacist before starting it.

9. What should I do if my lung cancer progresses despite treatment?

Ask the oncology team to review the diagnosis, imaging, previous treatment exposure and current options. Depending on the case, repeat biopsy, molecular testing, a clinical trial, a different systemic treatment or a local treatment may be appropriate. Progression does not by itself mean that every option has been exhausted.

10. Where can I find reliable, updated lung cancer treatment information?

Start with the National Cancer Institute's lung cancer treatment summaries and the American Society of Clinical Oncology's current thoracic cancer guidelines. The FDA's official drug approval announcements can clarify the original indication for particular medicines in the United States. Your local oncology team should verify which recommendations and approvals apply in your country.

References and Further Reading

The following resources support the clinical information and provide sources for continued reading. Treatment approvals and guideline recommendations evolve, so patients should check the latest version relevant to their location and circumstances.

Paul Marik. Lung Cancer in the Era of Precision Oncology: Epidemiology, Molecular Biology, and Therapeutic Challenges. October 3, 2026.
Read the original article.
Paul Marik. Lung Cancer Beyond Precision Oncology: The Five-Axis Metabolic Trap as a Systems Biology Framework. October 5, 2026.
Read the original article.
National Cancer Institute. Lung Cancer: Patient Information and Treatment Resources.
NCI lung cancer hub.
National Cancer Institute. Non-Small Cell Lung Cancer Treatment (PDQ®).
Clinical treatment summary.
National Cancer Institute. Small Cell Lung Cancer Treatment (PDQ®).
Clinical treatment summary.
American Society of Clinical Oncology. Thoracic Cancer Guidelines, including living guidelines for stage IV NSCLC.
Current ASCO guideline index.
Puri S, et al. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0. Journal of Clinical Oncology. 2026.
PubMed record.
Reuss JE, et al. Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1. Journal of Clinical Oncology. 2026.
PubMed record.
U.S. Food and Drug Administration. Approval of taletrectinib for ROS1-positive NSCLC, June 11, 2025.
FDA announcement.
U.S. Food and Drug Administration. Traditional approval of tarlatamab for extensive-stage SCLC, November 19, 2025.
FDA announcement.
National Cancer Institute. Cancer Therapy Interactions With Foods and Dietary Supplements (PDQ®).
NCI evidence and safety information.
National Cancer Institute. Complementary and Alternative Medicine for Cancer.
NCI patient resource.
National Cancer Institute. Lung Cancer Screening (PDQ®).
NCI screening evidence review.
National Cancer Institute. Clinical Trials for Non-Small Cell Lung Cancer.
Clinical trial search.

Editorial and medical disclaimer: This guide is for education and informed discussion with qualified healthcare professionals. It does not diagnose, prescribe or recommend an individualized treatment plan. Research descriptions are not endorsements of off-label drug use. The inclusion of an intervention or biological mechanism does not mean it is effective against lung cancer. Do not delay, discontinue or replace recommended cancer care based on this article.

Editorial approach: independent evidence review, explicit distinction between standard care and experimental interventions, and recognition of uncertainty where clinical validation is incomplete.